This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
AstraZeneca PLC (AZN.L) – Missed on its Q1 2018 earnings and revenue, revenue missed, coming in at $5.18bn against of $5.20bn expectations, its core earnings per share metric came in at $0.48 against $0.57 expected, a 9% miss, however it left its full year guidance unchanged. Closing price 5354.00p (Bloomberg)
Hikma Pharmaceuticals PLC (HIK.L) – For the full year, we continue to expect Injectable revenue to be within the range of $750m to $800m. We continue to expect competition to accelerate over the course of the year. We reiterate our expectations for generics revenues in 2018 in the range of $550m to $600m. Closing price 1395.50p (Reuters)
Lloyds Banking Group PLC (LLOY.LN), Barclays PLC (BARC.L) - Lloyds sells its Irish residential-mortgage portfolio to Barclays for £4bn, part of a strategy to become a low-risk, U.K.-focused bank. Closing prices 66.25p, 209.36p (Wall street Journal)
Ocado Group PLC (OCDO.L) – After yesterday’s stellar accent in the stocks share price, climbing as much as 80% and adding as much as £1.8bn to the company’s value, according to Bloomberg, may also pave the way for M&A options in the future. Closing price 798.4p (Bloomberg)
(Sources: Company newswires, Bloomberg, CNBC, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| MOTHERCARE | MTC | 24.4% | 33.6% | 4.7% |
| THOMAS COOK | TCG | -4.8% | -1.8% | -4.8% |
| EXPERIAN | EXPN | 5.6% | 6.1% | 2.0% |
| OCADO | OCDO | 44.4% | 81.2% | 26.8% |
| BRITISH LAND | BLND | 2.3% | 3.1% | 1.0% |
| WILLIAM HILL | WMH | 4.2% | 5.2% | -9.2% |
| GVC HOLDINGS | GVC | 5.0% | 5.0% | -6.6% |
| PADDY POWER BETFAIR | PPB | 1.9% | 3.1% | -4.6% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research